Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States
Perioperative pembrolizumab + SOC was found to be cost-effective versus SOC for the treatment of resectable LA HNSCC with CPS ≥ 1.
Authors
- Biruk Chafamo (ORCID: https://orcid.org/0000-0002-5728-3553)
- Yuexin Tang (ORCID: https://orcid.org/0000-0001-6528-4145)
- Dominic Muston (ORCID: https://orcid.org/0000-0003-4876-7940)
- Feng Qian (ORCID: https://orcid.org/0000-0002-1949-9193)
- Anjela Tzontcheva
- Catherine Fernan
- Geoffrey B. Johnson (ORCID: https://orcid.org/0000-0002-9781-4072)
- Arielle G. Bensimon (ORCID: https://orcid.org/0000-0003-1967-2045)
- D R Adkins
- K. Benjamin
- Dandan Zheng
- Ravindra Uppaluri
Institutions
- Brigham and Women's Hospital (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Harvard University (US)
- Washington University in St. Louis (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1080/13696998.2026.2633930
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00